SAN FRANCISCO--(BUSINESS WIRE)--Medivation, Inc. (NASDAQ:MDVN) today reiterated its rejection of Sanofi's substantially inadequate proposal to acquire the Company for $52.50 per share in cash, following the receipt of a letter from Sanofi. Medivation notes that Sanofi’s letter simply restates an inadequate proposal that the Medivation Board of Directors has already determined substantially undervalues the Company, its leading oncology franchise, and innovative late-stage pipeline. Medivation’s
![]()
↧